The relationship between Calcitonin and Creatine kinase levels in sera of newly diagnosed Iraqi patients with coronary artery disease
DOI:
https://doi.org/10.61841/py7ky124Keywords:
Coronary artery disease, Calcitonin, Creatine kinase, GenderAbstract
One of the most serious heart diseases and May lead to sudden cardiac death is the coronary artery disease (CAD). Meanwhile, CAD diagnoses are very expensive and time-consuming. The propose of this work was to evaluate the levels of calcitonin (CT) and serum creatine kinase (CK) in newly diagnosed CAD patients. This study was conducted on 54 patients with CAD disease, including (23 female and 31 male), with age for male patients (56.61 ± 9.71) and (56.27 ± 9.22) for female patients, in addition to 54 healthy volunteers, including (23 females and 31 males) groups of matched control. After obtaining serum samples from separate patient and control groups, the measuring values for CK and CT were done using ELISA method and the data of analysis was carried out using the SPSS. The results of the study showed statistically high significant serum CK activities (660.24 ± 27.275), (653.18 ± 34.747) in male and female patients respectively, compared to the control group (69.19 ± 8.299), (89.54 ± 10.998), respectively. Similarly, there was a significant increase in the level of CT in the male patients as compared to female patients as it was as mean± SD (10.48 ± 0.375), (9.56 ± 0.453), respectively. When compared to the control males and females, the mean was ± SD (8.82 ± 0.389), (8.44 ± 0.434), respectively. There was also a negative association between CT and CK (r = -0.065) in females and a positive relationship (r = 0.294) in males, both of which were unimportant. There was a negative relationship between CT and age, in both patient groups, when compared with the other group (control). In regard to the relationship between CK and age, the positive relationship (r = 0.034) had a negative correlation, in males (r = -0.178) and in females, when compared to the control groups. Age and gender variables and family history of diabetes were taken into account and it was found that the difference is significant between the two groups. Because the relationship of serum levels CT and CK with CAD severity is unknown, the case presented here highlights the importance of serum CT and serum CK levels in differential diagnosis of coronary disease (CAD).
Downloads
References
1. Wong N.D., Epidemiological studies of CHD and the evolution of preventive cardiology. Nature Reviews Cardiology, 11(5)276-289 (2014).
2. Department of Public Health and Primary Care, University of Cambridge, High-risk Hearts: A South Asian Epidemic. (2013). Available from: http://www.phpc.cam.ac.uk/blog/high-risk-hearts-a-south-asian-epidemic.
3. Levy D., and Kannel W.B., Searching for answers to ethnic disparities in cardiovascular risk. The Lancet,
356(9226), 266-267(2000).
4. Wah T.Y., Gopal Raj R., and Iqbal U. Automated diagnosis of coronary artery disease: A review and workflow.
Cardiology research and practice, 2018, (2018).
5. Schenck, Patricia A., Thomas J., Rosol, in Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice, 4th edition. Elsevier Saunders, St. Louis, Missouri, USA (2012).
6. Goodman H.M., Basic medical endocrinology, 3rd edition. Academic Press, Waltham, (2003).
7. Lott JA, and Nemesansky E. Creatine kinase,166-182(1966) in Lott, J. A., & Wolf, P. L. (Eds.). (1986). Clinical enzymology: a case-oriented approach. Year Book Medical Pub.
8. Vatner D. E., and Ingwall J. S., Effects of moderate pressure overload cardiac hypertrophy on the distribution of creatine kinase isozymes." Proceedings of the Society for Experimental Biology and Medicine 175(1) 5-9(1984).
9. Younes A., Schneider J.M., Bercovici J, Swynghedauw B. Redistrubuiton of creatine kinase isoenzymes inchronically overloaded myocardium. Cardiovasc Res, 19,15-19(1985).
10. Ingwall JS, Kramer MF, Fifer M.A., Lorell B.H., Shemin R., Grossman W., and Allen P.D., The creatinekinase system in normal and diseased human myocardium. New Engl J Med, 313(10),1050-1054.10(1985).
11. Nascimben L., Ingwall J.S., Pauletto P., Friedrich J., Gwathmey J.K., Saks V., Pessina A.C., and Allen P.D., Creatine kinase system in failing and nonfailing human myocardium. Circulation, 94, 1894-1901(1996).
12. Martins C.S., Rodrigues M.J.O., Miranda V.P., and Nunes J.P.L., Prognostic value of cardiac TnI in patients with COPD acute exacerbation. Netherlands Journal of Medicine 67, 341-349(2009).
13. Davies, R.E., and Rier, J. D., Gender Disparities in CAD: Women and Ischemic Heart Disease. Current atherosclerosis reports, 20(10), 51(2018).
14. Moßhammer D., Muche R., Menzel D., Ring C., Wernet D., Meisner C., Gleiter C.H., Lorenz G., and Mörike K., Pairs of Creatine Kinase Serum Activity. The Open Clinical Chemistry Journal, 2, 12-15(2009).
15. Goodman H.M., Basic medical endocrinology, 3rd edn. Academic Press, Waltham (2003).
16. Niccoli P., Brunet P., Roubicek C., Roux F., Baudin E., Lejeune P.J., and Conte-Devolx B., Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. European journal of endocrinology, 132(1), 75-81(1995).
17. Martinez M.E., Miguel J.L., Gomez P., Selgas R., Salinas M., Gentil, M., and Sánchez, L.S. Plasma calcitonin concentration in patients treated with chronic dialysis: Differences between hemodialysis and CAPD. Clinical nephrology, 19(5), 250-253(1983).
18. Hashemipour S.V., Pourhosseini H., and Hosseinsabet A., Correlation between the serum procalcitonin level and the extension and severity of coronary artery disease in patients with non-ST-segment elevation myocardial infarction. Cardiovasc Endocrinol Metab., 8(2), 62-66(2019).
19. Kanbay M., Wolf M., Selcoki Y., Solak Y., Ikizek M., Uysal S., Segall L., Armutcu F., Eryonucu B., Duranay M., Goldsmith D., and Covic A., Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease” Int Urol Nephrol, 44, 1169-1175(2012).
20. Strunz C.M., Araki L.M., Nogueira A.A., and Mansur A.P., Gender differences in serum CK-MB mass levels in healthy Brazilian subjects. Braz J Med Biol Res. 44(3), 236-239(2011).
21. Zhang Y., Chen Z., Tang Y., Shan W., Wang L., Shi J., and Xu G., Association between procalcitonin levels and carotid atherosclerosis in acute ischemic stroke patients. International Journal of Neuroscience, 128(3), 237- 242(2018).
22. Jacob M.P., Moura A. M., Tixier J.M., Lafuma C., Robert A.M., Robert L., and Worcel M., Prevention by calcitonin of the pathological modifications of the rabbit arterial wall induced by immunization with elastin peptides: Effect on vascular smooth muscle permeability to ions. Experimental and molecular pathology, 46(3), 345-356(1987).
23. Güneş S., Akarsu C., Sar M., Çelik M., and Mert M., Serum Calcitonin Levels may be used in the Differential Diagnosis of Vagal Glomus. Otolaryngol Open J., 3(1): 22-26(2017).
24. Christodoulidis G., Vittorio T.J., Fudim M., Lerakis S., Kosmas C.E., Inflammation in coronary artery disease.
Cardiol Rev., 22, 279-288(2014).
25. Herrmann J., and Lerman A., The endothelium: dysfunction and beyond. Journal of Nuclear Cardiology, 8(2), 197-206 (2001).
26. Atheeb A.k., and Hussein S.Z. Correlation of Myeloperoxidase Activity with Malondealdehyde Levels in Iraqi patients with Coronary Artery Diseases, JGPT,12(1),565-572 (2020).
27. Koller A., Balasko M., and Bagi Z., Endothelial regulation of coronary microcirculation in health and cardiometabolic diseases, Internal and Emergency Medicine, 8(1), S51-S54(2013).
28. Moisa S.S., Nozdrachev A.D., Calcitonin and Parathyrin are Glucoregulating Hormones. Journal of Molecular and Genetic Medicine 024, S1(2014).
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
